Shanghai Cless Biotech Co., Ltd. (Clessbio), founded in 2024 and based in Shanghai’s biopharmaceutical ecosystem, is dedicated to the development of breakthrough therapies.
With a mission to address global unmet clinical needs, the company focuses on key therapeutic areas including autoimmune diseases, metabolic disorders, and endocrinology, striving to become an internationally competitive R&D engine for both first-in-class and best-in-class novel drugs.
